Displaying 1–16 of 16 results for Emil W. Ciurczak, Chief Technical Officer, Cadrai Group
cGMPS are essential, but when cGMP dogma triumphs over common sense and prevents innovation, were all in trouble, says NIR expert and pharmaceutical industry consultant, Emil Ciurczak. He offers some tips for drawing the line between compliance and absurdity.
NIR expert Emil Ciurczak thinks prosperity and the Internet are making today's graduates far too complacent and out of touch for their own good. Networking and professional societies are at risk, he says, and drug manufacturing will be worse off for it.
NIR expert Emil Ciurczak asks whether PAT will eliminate the need for traditional USP product release tests and concludes that theyre still essential as a reference method and important in minimizing liability.
Beware of process control software that is not PAT-specific, cautions Emil Ciurczak. He cites Excel, with its rounding errors, as a prime example of software written without the input of science-types.
PAT and analytical services dont always mix, as PAT columnist Emil Ciurczak relates. His advice: Dont allow your PAT group to become a stepchild. Ensure that it receives credit for PAT-based improvements.
NIR expert and Pharmaceutical Manufacturing columnist Emil Ciurczak discusses this year's conference in this downloadable audio file. For his article discussing highlights and key developments, see "IFPAC 2006 Under the Microscope."
"NIR person" and physical chemist Emil Ciurczak provides a thorough analysis of this year's IFPAC conference, held Feb. 21-23 in Arlington, Va.
Columnist Emil Ciurczak urges pharmaceutical manufacturers to realize that FDA personnel and instrument vendors are on their side, and that talking with them about PAT will be more fruitful than relying on word of mouth.
Attention, corporate bean counters: PAT is not a magic bullet for reducing QC headcounts. In fact, it may require hiring more people, but the efforts will pay off in improved efficiencies and lower costs.
Emil Ciurczak reviews Decembers conference, which broke with tradition by focusing more on the business than the technical side of PAT.
Dont be penny-wise but pound-foolish during early planning and budgeting stages, and never base decisions on equipment sticker prices without considering savings in time to market.
Pharmaceutical processing & engineering: A consultant ponders the question, as it relates to NIR and pharmaceutical process analytical technology (PAT) projects that require a high level of hard-to-find technical expertise.
Pharmaceutical processing & engineering: Last year at the IFPAC conference, NIR guru Emil Ciurczak bemoaned the fact that PAT was being promoted by geeks for geeks. Now, however, he notes that an upcoming summit may lead the charge toward a new emphasis on convincing corporate and financial ...